We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Amneal Pharmaceuticals Inc
16 own
24 watching
Current Price
$2.34
$-0.05
(-2.09%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
711.89M
52-Week High
3.77
52-Week Low
1.24
Average Volume
3.12M
Dividend Yield
--
P/E Ratio
84.6746
Market Capitalization711.89M52-Week High3.7752-Week Low1.24Average Volume3.12MDividend Yield--P/E Ratio84.6746What does the Amneal Pharmaceuticals Inc do?
Amneal Pharmaceuticals, Inc., formerly known as Atlas Holdings, Inc. (the "Company"), was formed along with its wholly owned subsidiary, K2 Merger Sub Corporation, a Delaware corporation ("Merger Sub"), on October 4, 2017, for the purpose of facilitating the combination of Impax Laboratories, Inc. (now Impax Laboratories, LLC), a Delaware corporation then listed on the Nasdaq Stock Market ("Impax") and Amneal Pharmaceuticals LLC, a Delaware limited liability company ("Amneal").
Read More
How much money does Amneal Pharmaceuticals Inc make?
News & Events about Amneal Pharmaceuticals Inc.
Business Wire
27days ago
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) announced its actual results today for the first quarter ended March 31, 2023. We are very pleased with our strong first quarter results and start to 2023. We are confident in our continued momentum driven by the broad-based strength...
Ticker Report
1month ago
Amneal Pharmaceuticals, Inc. (NYSE:AMRX Get Rating) has received a consensus rating of Moderate Buy from the six ratings firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and three have given a buy...
Business Wire
1month ago
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2023 financial results on Friday May 5, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 5...
Zolmax
1month ago
Amneal Pharmaceuticals, Inc. (NYSE:AMRX Get Rating) has earned a consensus recommendation of Moderate Buy from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy ...
Ticker Report
2 months ago
Amneal Pharmaceuticals (NYSE:AMRX Get Rating) had its price target dropped by Truist Financial from $5.00 to $4.00 in a research note issued to investors on Wednesday, The Fly reports. The brokerage currently has a buy rating on the stock. Truist Financials target price ...
Frequently Asked Questions
Frequently Asked Questions
What is Amneal Pharmaceuticals Inc share price today?
Can Indians buy Amneal Pharmaceuticals Inc shares?
How can I buy Amneal Pharmaceuticals Inc shares from India?
Can Fractional shares of Amneal Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Amneal Pharmaceuticals Inc stocks?
What is today’s traded volume of Amneal Pharmaceuticals Inc?
What is today’s market capitalisation of Amneal Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Amneal Pharmaceuticals Inc?
What percentage is Amneal Pharmaceuticals Inc down from its 52-Week High?
What percentage is Amneal Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$2.34
$-0.05
(-2.09%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.